Compare OLP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | PLRX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 79.9M |
| IPO Year | 1995 | 2020 |
| Metric | OLP | PLRX |
|---|---|---|
| Price | $21.44 | $1.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.50 | $2.67 |
| AVG Volume (30 Days) | 68.3K | ★ 460.8K |
| Earning Date | 03-05-2026 | 03-11-2026 |
| Dividend Yield | ★ 8.12% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | $4.40 | N/A |
| P/E Ratio | $19.27 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $1.09 |
| 52 Week High | $26.63 | $1.95 |
| Indicator | OLP | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 39.02 |
| Support Level | $20.09 | $1.12 |
| Resistance Level | $21.64 | $1.39 |
| Average True Range (ATR) | 0.56 | 0.07 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 2.18 | 8.77 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.